GENMAB A/S (GMAB) Form 6-K — Oct 28, 2026
Genmab announced that its Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab met both primary endpoints at the first interim analysis in first-line PD-L1-positive recurrent/metastatic head and neck cancer. The combination reduced the risk of death by 50% (OS HR 0.50, p<0.0001) and improved objective response rate (odds ratio 3.17, p<0.0001) versus pembrolizumab alone, regardless of HPV status. The safety profile was generally well tolerated with no new safety signals identified. Genmab plans to engage global regulatory authorities and will submit full results for presentation at a future medical meeting; the company will host an investor update the same day.
Key figures
- Trial
- LiGeR-HN1 (NCT06525220)
- Os p value
- <0.0001
- Orr p value
- <0.0001
- Orr odds ratio
- 3.17 (95% CI, 2.06, 4.89)
- Os hazard ratio
- 0.50 (95% CI, 0.37, 0.67)
- Risk of death reduction
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.